Aravive Added to the Russell 2000® and Russell 3000® Indexes
June 30 2020 - 4:05PM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage
biopharmaceutical company developing treatments designed to halt
the progression of life-threatening diseases, including cancer and
fibrosis, today announced that the Company has been added to
the Russell 2000® and Russell 3000® Indexes, effective June 29,
2020, as part of the 2020 Russell U.S. indexes reconstitution.
“Our inclusion in the Russell indexes reflects the meaningful
progress we have made toward our goal of changing the treatment
paradigm for people living with cancer,” said Gail McIntyre, Ph.D.,
chief executive officer of Aravive. “We believe our inclusion will
enhance Aravive’s visibility within the investment community and
have a positive impact on the liquidity of our stock.”
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets
are benchmarked against Russell’s U.S. indexes. Russell indexes are
part of FTSE Russell, a leading global index provider. For more
information on the Russell 2000® and Russell 3000® Indexes and the
Russell indexes reconstitution, go to the “Russell Reconstitution”
section on the FTSE Russell website.
About AraviveAravive, Inc. (Nasdaq:
ARAV) is a clinical-stage biopharmaceutical company developing
treatments designed to halt the progression of life-threatening
diseases, including cancer and fibrosis. Aravive’s lead product
candidate, AVB-500, is an ultra-high affinity decoy protein that
targets the GAS6-AXL signaling pathway. By capturing serum GAS6,
AVB-500 starves the AXL pathway of its signal, potentially halting
the biological programming that promotes disease progression. AXL
receptor signaling plays an important role in multiple types of
malignancies by promoting metastasis, cancer cell survival,
resistance to treatments, and immune suppression. The GAS6-AXL
signaling pathway also plays a significant role in
fibrogenesis. Aravive is actively evaluating AVB-500 in
platinum-resistant ovarian cancer and clear cell renal cell
carcinoma and intends to expand development into additional
oncology indications. Aravive is based in Houston,
Texas and received a Product Development Award from
the Cancer Prevention & Research Institute of
Texas (CPRIT) in 2016. For more information, please
visit www.aravive.com.
Forward-Looking StatementsThis press release
includes forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995 on our current
expectations and projections about future events. In some cases,
forward-looking statements can be identified by terminology such as
“may,” “should,” “potential,” “continue,” “expects,” “anticipates,”
“intends,” “plans,” “believes,” “estimates,” and similar
expressions, and include statements such as the inclusion in the
Russell 2000® and Russell 3000® enhancing the Company’s visibility
within the investment community and having a positive impact on the
liquidity of its stock and the expansion of the development of
AVB-500 into additional oncology and fibrotic indications.
Forward-looking statements are based on current beliefs and
assumptions, are not guarantees of future performance and are
subject to risks and uncertainties that could cause actual results
to differ materially from those contained in any forward-looking
statement as a result of various factors, including, but not
limited to, risks and uncertainties related to: the impact of the
inclusion in the Russell 2000® and Russell 3000® of the Russell,
the ability to properly fund the Company, the ability of the
directors and management team to deliver on the Company’s strategic
vision and execute on its business plan, the impact of COVID-19 on
the Company’s clinical strategy and fundraising, the Company’s
ability to expand development into additional oncology and fibrotic
indications, the Company’s dependence upon AVB-500, AVB-500’s
ability to have favorable results in clinical trials, the clinical
trials of AVB-500 having results that are as favorable as those of
preclinical and clinical studies, the ability to receive regulatory
approval, potential delays in the Company's clinical trials due to
regulatory requirements or difficulty identifying qualified
investigators or enrolling patients especially in light of the
COVID-19 outbreak; the risk that AVB-500 may cause serious side
effects or have properties that delay or prevent regulatory
approval or limit its commercial potential; the risk that the
Company may encounter difficulties in manufacturing AVB-500; if
AVB-500 is approved, risks associated with its market acceptance,
including pricing and reimbursement; potential difficulties
enforcing the Company's intellectual property rights; the Company's
reliance on its licensor of intellectual property and financing
needs. The foregoing review of important factors that could cause
actual events to differ from expectations should not be construed
as exhaustive and should be read in conjunction with statements
that are included herein and elsewhere, including the risk factors
included in the Company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2019, recent Current Reports on Form
8-K and subsequent filings with the SEC. Except as required by
applicable law, the Company undertakes no obligation to revise or
update any forward-looking statement, or to make any other
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts: Media:Sheryl Seapy,
W2Osseapy@w2ogroup.com(213) 262-9390
Investors: Luke Heagle, W2O lheagle@w2ogroup.com (910)
726-1372
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Sep 2023 to Sep 2024